Correspondence 0001193125-24-274852 from CG Oncology, Inc. (CGON) (CIK 0001991792) (CGON)
CG Oncology, Inc. (CGON) (CIK 0001991792)
Date: Dec. 11, 2024 · CIK: 0001991792 · Accession: 0001193125-24-274852
AI Filing Summary & Sentiment
File numbers found in text: 333-283725
Letter
CG Oncology, Inc.
400 Spectrum Center Drive, Suite 2040
Irvine, CA 92618
December 11, 2024
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tamika Sheppard
Re: CG Oncology, Inc.
Registration Statement on Form S-1 (File No. 333-283725)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, CG Oncology, Inc. (the “Company”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on December 12, 2024, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP at (212) 479-6474 or, in his absence, Charles S. Kim of Cooley LLP at (858) 550-6049.
Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
[Signature Page Follows]
Very truly yours,
CG Oncology, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP CG Oncology, Inc. 400 Spectrum Center Drive, Suite 2040 Irvine, CA 92618 December 11, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: CG Oncology, Inc. Registration Statement on Form S-1 (File No. 333-283725) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, CG Oncology, Inc. (the “Company”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on December 12, 2024, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP at (212) 479-6474 or, in his absence, Charles S. Kim of Cooley LLP at (858) 550-6049. Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement. [Signature Page Follows] Very truly yours, CG Oncology, Inc. /s/ Arthur Kuan By: Arthur Kuan Title: Chief Executive Officer cc: Arthur Kuan, Chairman and Chief Executive Officer, CG Oncology, Inc. Corleen Roche, Chief Financial Officer, CG Oncology, Inc. Joshua Patterson, General Counsel and Chief Compliance Officer, CG Oncology, Inc. Divakar Gupta, Cooley LLP Charles S. Kim, Cooley LLP Matthew T. Bush, Latham & Watkins LLP Anthony Gostanian, Latham & Watkins LLP